touchEXPERT OPINIONS Monoclonal antibody biosimilars in the treatment of solid tumours: Perspectives for pharmacists
Find out how monoclonal antibody (MAb) biosimilars are developed and learn about the practical aspects of their use in oncology pharmacy.
Dr Cornes outlines the development and regulatory pathway for biosimilars, and discusses real-world experiences of switching from reference biologics to biosimilars.1/3 Next Interview
Dr Bubalo discusses the formulation and immunogenic potential of MAb biosimilars for the treatment of solid tumours, and overviews management approaches for infusion-related reactions.2/3 Next Interview
Mr Nomura describes how handling in the pharmacy affects the stability of MAb biosimilars, and overviews the practical steps for preparing and storing them in the hospital pharmacy.3/3 Leave Feedback
Learning Objectives & Overview
In this activity, three leading experts share their insights on using MAbs in oncology practice. Topics include the concepts of comparability, interchangeability and extrapolation, managing variations in biosimilar formulations, and how biosimilars should be handled and stored in the hospital pharmacy.
This activity has been designed to meet the educational needs of pharmacists, oncology pharmacists and hospital pharmacists involved in the clinical screening, preparation and dispensing of MAb biologics for the treatment of solid tumours.
After watching this activity, participants should be better able to:
- Understand the biosimilar concepts of comparability, interchangeability and extrapolation
- Compare formulations of biosimilars and reference products to inform prescribing choice
- Appreciate how handling in the pharmacy affects biosimilar and reference product stability
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinion
- Interactive CME and e-learning modules
- Video conference highlights